Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin 3-month Formulation in Chinese Children With Central Precocious Puberty
NCT04736602Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin pamoate in central precocious puberty (CPP), sponsored by Ipsen. Primary endpoint: Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation at Month 3. Started Mar 2021; status: completed.
02
Drugs
triptorelin pamoate
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT04736602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736602.